Tracking AI/LLM Literacy and Knowledge in Urology Outpatients (TALK-U)

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

About this trial

This study is a one-time, questionnaire-based survey of adults attending a urology outpatient clinic. The investigators will examine whether patients who use AI chat tools based on large language models (LLMs), such as ChatGPT, before seeking care differ from non-users in (1) anxiety, (2) satisfaction with the clinic visit, and (3) awareness/understanding of their health condition.

Participants who provide written informed consent will complete a brief survey during their clinic visit (about 5-7 minutes). The survey includes a standardized anxiety scale (GAD-7), visual analog scales (0-10) for anxiety before and after the visit, satisfaction, and disease awareness, as well as questions about AI/LLM knowledge and use. Treating clinicians will not have access to participants' survey responses, and participation will not affect clinical care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years or older

First-time visit to the Urology Outpatient Clinic

Able to read and write and complete the questionnaire independently

Able to provide written informed consent

Disqualifiers

Age under 18 years

Insufficient literacy to understand and complete the questionnaire

Severe hearing or visual impairment, or a neurological/psychiatric condition that prevents understanding and completing the survey

Refusal or inability to provide informed consent

Trial population

Adult patients (≥18 years) presenting for a first-time visit to the Urology Outpatient Clinic at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital will be invited to participate during a 2-month recruitment period. Participants who provide written informed consent and can complete a brief questionnaire independently will be enrolled. The study will include both sexes and a broad range of urologic presenting complaints.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

400 Participants
are grouped into 2 trial groups
Group A: AI/LLM users
Group B: non AI/LLM users

Trial outcomes

Primary outcomes

1

Pre-visit Anxiety (VAS 0-10)

Self-rated anxiety on a 0-10 visual analog scale (VAS), where 0 indicates no anxiety and 10 indicates the highest possible anxiety. This measure reflects visit-related state anxiety prior to clinician encounter.

Time frame
Day 0 (immediately before the outpatient visit)

Secondary outcomes

1

Post-visit Anxiety (VAS 0-10)

Self-rated anxiety on a 0-10 VAS (0 = none, 10 = highest).

Time frame
Day 0 (immediately after the outpatient visit)
2

Visit Satisfaction (VAS 0-10)

Self-rated satisfaction with the outpatient visit on a 0-10 VAS (0 = not satisfied at all, 10 = maximum satisfaction).

Time frame
Day 0 (immediately after the outpatient visit)
3

Disease Awareness/Understanding (VAS 0-10)

Self-rated awareness/understanding of one's condition on a 0-10 VAS (0 = none, 10 = complete).

Time frame
Day 0 (during the outpatient clinic visit)

Other outcomes

1

Baseline General Anxiety Symptoms (GAD-7 Total Score)

Total score on the 7-item GAD-7 questionnaire (range 0-21; higher scores indicate greater generalized anxiety symptoms). This measure will be used to account for baseline anxiety (trait-like symptoms) and to adjust analyses of VAS-based state anxiety out

Time frame
Day 0 (at enrollment; prior to or during the clinic visit)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: